Bristol-Myers Squibb Company (BMY)

NYSE: BMY · Real-Time Price · USD
43.80
+0.26 (0.60%)
At close: Oct 14, 2025, 4:00 PM EDT
43.94
+0.14 (0.32%)
After-hours: Oct 14, 2025, 7:59 PM EDT
0.60%
Market Cap89.15B
Revenue (ttm)47.70B
Net Income (ttm)5.05B
Shares Out 2.04B
EPS (ttm)2.49
PE Ratio17.62
Forward PE6.93
Dividend$2.48 (5.66%)
Ex-Dividend DateOct 3, 2025
Volume16,803,873
Open43.43
Previous Close43.54
Day's Range43.27 - 43.90
52-Week Range42.96 - 63.33
Beta0.34
AnalystsHold
Price Target57.54 (+31.37%)
Earnings DateOct 30, 2025

About BMY

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthrit... [Read more]

Sector Healthcare
Founded 1887
Employees 34,100
Stock Exchange NYSE
Ticker Symbol BMY
Full Company Profile

Financial Performance

Financial Statements

Analyst Summary

According to 14 analysts, the average rating for BMY stock is "Hold." The 12-month stock price target is $57.54, which is an increase of 31.37% from the latest price.

Price Target
$57.54
(31.37% upside)
Analyst Consensus: Hold
Stock Forecasts

News

Final Trade: WMT, AMZN, F, BMY

The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.

Other symbols: AMZNWMTF
6 hours ago - CNBC Television

Stock Looks Undervalued As Bristol Myers Buys Orbital Therapeutics

Bristol Myers Squibb remains undervalued, ranking 12th on my Magic Formula screen with strong earnings yield and capital returns amongst the S&P 500. Company pivoting from small-molecule drugs to mRNA...

1 day ago - Seeking Alpha

Bristol Myers Squibb to Present Data at ESMO® 2025 Showcasing Progress of Oncology Portfolio Across Diverse Tumor Types

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ESMO--Bristol Myers Squibb to Present Data at ESMO® 2025 Showcasing Progress of Oncology Portfolio Across Diverse Tumor Types.

1 day ago - Business Wire

SystImmune to Receive Milestone Payment from Bristol Myers Squibb Under Iza-Bren Collaboration

REDMOND, Wash. , Oct. 13, 2025 /PRNewswire/ -- SystImmune, Inc., a clinical-stage biotechnology company, today announced the treatment of the first patient in the IZABRIGHT-Breast01 study (NCT06926868...

1 day ago - PRNewsWire

Buy Any Of 14 IDEAL 'Safer' S&P 500 October Dividend Dogs

Fourteen of the highest-yielding, 'safer' S&P 500 dividend stocks are currently attractively priced, with free cash flow supporting their payouts. Top ten S&P 500 dividend 'dogs' are projected to deli...

Other symbols: AESAMCRARECAGCPBDOCDOW
2 days ago - Seeking Alpha

Bristol Myers Squibb: Value Emerges From Distress

Bristol Myers Squibb offers a compelling value entry for long-term income investors, despite looming patent cliffs and execution risks. BMY's growth portfolio is positioned to offset revenue losses fr...

3 days ago - Seeking Alpha

Bristol Myers buys Orbital Therapeutics for $1.5 billion

Drugmaker Bristol Myers Squibb said on Friday it will acquire privately held cell therapy developer Orbital Therapeutics for $1.5 billion in cash.

4 days ago - Reuters

Bristol Myers Squibb Strengthens and Diversifies Cell Therapy Portfolio with Acquisition of Orbital Therapeutics

PRINCETON, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Bristol Myers Squibb Strengthens and Diversifies Cell Therapy Portfolio with Acquisition of Orbital Therapeutics.

4 days ago - Business Wire

Bristol Myers Squibb and TV Host Gail Simmons Tackle Stigma in Schizophrenia with New Initiative Spotlighting the Power of Support and Connection

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #COBENFY--Bristol Myers Squibb and TV Host Gail Simmons Tackle Stigma in Schizophrenia with New Campaign Spotlighting the Power of Support and Connection.

4 days ago - Business Wire

Bristol-Myers Squibb: Your Chance To Buy A Bargain 6% Yield

Bristol-Myers Squibb offers a compelling value at current lows, trading at under 7x earnings and yielding an attractive 6% dividend. BMY's resilient business model, strong cash flow, and growth from n...

5 days ago - Seeking Alpha

My Top 5 Biotech Stocks Big Pharma Could Buy Next

While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of ...

8 days ago - Seeking Alpha

Final Trade: GDX, PFE, GFS, BMY

The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.

Other symbols: GDXGFSPFE
13 days ago - CNBC Television

‘Fast Money' traders talk opportunities in health care stocks

The Fast Money traders discuss why health care stocks look attractive on valuations, how underweight positioning could drive sustainability, why recent White House policy moves may be a “gift” to phar...

13 days ago - CNBC Television

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...

Other symbols: GSKXRAY
13 days ago - Benzinga

Bristol Myers Squibb's Anti-MTBR-Tau-Targeting Antibody, BMS-986446, Granted Fast Track Designation by U.S. FDA for the Treatment of Alzheimer's Disease

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Alzheimers--BMS's Anti-MTBR-Tau-Targeting Antibody, BMS-986446, Granted Fast Track Designation by U.S. FDA for the Treatment of Alzheimer's Disease.

13 days ago - Business Wire

Bristol Myers, Takeda to pool data for AI-based drug discovery

Bristol Myers Squibb , Takeda Pharmaceuticals and Astex Pharmaceuticals are coming together to share proprietary data for training an artificial intelligence model to assist drug discovery and develop...

Other symbols: TAK
13 days ago - Reuters

7 Ideal "Safer" Dividend Buys From 61 September Graham Value All-Stars (GVAS)

The article analyzes Large Cap Value (GASV) stocks using YCharts' Value Score and the Ben Graham Formula to identify fair-priced, high-yield dividend opportunities. Seven of fourteen 'safer' lowest-pr...

Other symbols: BBVACMCSAEEPDETMFCMO
14 days ago - Seeking Alpha

Buy 7 Barron's Better Bets (Than T-Bills) From 15 'Safer' Of 23 September Dividend Dogs

Seven of the top fifteen Barron's Better Bets (BBB) dividend 'dogs' - including CAG, PFE, VZ, BMY, UDR, KIM, and KEY - are attractively priced for income investors. Analyst forecasts project 17.61% to...

Other symbols: BBYCAGEQRKEYKIMKMILYB
16 days ago - Seeking Alpha

Portal Innovations' John Flavin: Tariffs on pharma could raise costs and delay drug access

John Flavin, Portal Innovations founder and CEO, joins CNBC's 'Squawk on the Street' to discuss the Trump administration's proposed pharmaceutical tariffs, the impact on biotech startups and clinical ...

Other symbols: ABBVLLYMRKPFEBIIB
18 days ago - CNBC Television

Bristol Myers to sell psoriasis drug at over 80% discount

Bristol Myers Squibb said on Thursday it will sell its psoriasis drug Sotyktu directly to cash-paying patients at a more than 80% discount to the drug's list price.

19 days ago - Reuters

Bristol Myers Squibb Builds on Eliquis® (apixaban) Direct-to-Patient Program, Announces New BMS Patient Connect Platform Offering Sotyktu® (deucravacitinib)

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Builds on Eliquis® (apixaban) Direct-to-Patient Program, Announces New BMS Patient Connect Platform Offering Sotyktu®.

19 days ago - Business Wire

Bristol-Myers Squibb Company (BMY) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum Transcript

Bristol-Myers Squibb Company (NYSE:BMY) Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum September 23, 2025 9:40 AM EDT Company Participants Lynelle Hoch - Presiden...

21 days ago - Seeking Alpha

Bristol Myers Squibb Announces Phase 3 EXCALIBER-RRMM Study Evaluating Iberdomide in Combination with Standard Therapies Demonstrated a Significant Improvement in Minimal Residual Disease Negativity Rates in Relapsed or Refractory Multiple Myeloma

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb Announces Phase 3 EXCALIBER-RRMM Study Evaluating Iberdomide in Combination with Standard Therapies.

21 days ago - Business Wire

Buy Bristol Myers Squibb Stock At $45?

Bristol-Myers Squibb (NYSE: BMY) has considerably lagged behind the overall market, with its stock decreasing by 20% this year, while the S&P 500 index has risen by 14%. This drop can be attributed in...

21 days ago - Forbes

Bristol Myers plans to launch schizophrenia drug in UK at list price equal to the US

Bristol Myers Squibb said on Monday that it plans to launch its schizophrenia treatment Cobenfy in the UK in 2026 at a price that is equal to its US list price.

22 days ago - Reuters